InMode (INMD) vs Stereotaxis (STXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InMode (INMD) has outperformed Stereotaxis (STXS) over the past year, losing 6.4% versus a loss of 68.9%. Over five years, STXS leads with a -81.3% price change compared with -83.1% for INMD. InMode is the larger company by market cap ($810.2 million vs $111.2 million), about 7.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INMD | STXS |
|---|---|---|
| Share price | $14.08 | $1.11 |
| Market cap | $810.22M | $111.22M |
| 1-day change | +0.50% | -1.77% |
| YTD return | -4.15% | -51.74% |
| 1-year return | -6.45% | -68.91% |
| 5-year return | -83.11% | -81.28% |
| P/E ratio (TTM) | 11.64 | — |
| Forward P/E | 10.26 | — |
| EPS (TTM) | $1.21 | $-0.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.67 | $3.42 |
| 52-week low | $12.72 | $1.09 |
| Distance from 52-week high | -15.54% | -67.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +14.84% | +170.27% |
| Average volume | 501.37K | 808.41K |
| Shares outstanding | 57.54M | 100.20M |
| Employees | 660 | 131 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Instruments & Supplies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- InMode is about 7.3 times larger than Stereotaxis by market value ($810.22M vs $111.22M).
- INMD has outperformed STXS by 62.5 percentage points over the past year.
- The two companies sit in different sectors: InMode in Health Care and Stereotaxis in Healthcare.
About InMode
INMD stock →InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 660 employees
About Stereotaxis
STXS stock →Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally.
Healthcare · Medical Instruments & Supplies · 131 employees
INMD vs STXS FAQ
Which is bigger, InMode or Stereotaxis?
InMode (INMD) is larger, with a market capitalization of $810.22M compared with $111.22M for Stereotaxis (STXS).
Which stock has performed better over the past year, INMD or STXS?
INMD returned -6.45% over the past 12 months, compared with -68.91% for STXS (price return, excluding dividends). Past performance does not predict future results.
Are InMode and Stereotaxis in the same industry?
No. InMode is in the Health Care sector, while Stereotaxis is in Healthcare.